1-10 of 10
Mark N. Stein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Heather J. Chalfin, Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak, Yen-Lin Chu, Robin Richardson, Rachel Krupa, Amanda K.L. Anderson, Yipeng Wang, Ryan Dittamore, Sumanta K. Pal, Primo N. Lara, Mark N. Stein, David I. Quinn, Seth M. Steinberg, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Rene Costello, Jacqueline Cadena, Carlos Diaz, James L. Gulley, William L. Dahut, Howard Streicher, John J. Wright, Jane B. Trepel, Donald P. Bottaro, Andrea B. Apolo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1391–1398.
https://doi.org/10.1158/1078-0432.CCR-20-2891
Published: 01 March 2021
View article titled, Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer
Open the PDF for Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary-Ellen Taplin, James Babb, Ethan S. Barnett, Alejandro Gomez-Pinillos, Xiaomei Liu, Dirk Moore, Robert DiPaola, Tomasz M. Beer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2672.
https://doi.org/10.1158/1078-0432.CCR-19-0442
Published: 15 April 2019
View article titled, Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Open the PDF for Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer in another window
Journal Articles

Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary-Ellen Taplin, James Babb, Ethan S. Barnett, Alejandro Gomez-Pinillos, Xiaomei Liu, Dirk Moore, Robert DiPaola, Tomasz M. Beer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 52–63.
https://doi.org/10.1158/1078-0432.CCR-18-1589
Published: 03 January 2019
View article titled, Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Open the PDF for Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

Channing J. Paller, Xian C. Zhou, Elisabeth I. Heath, Mary-Ellen Taplin, Tina Mayer, Mark N. Stein, Glenn J. Bubley, Roberto Pili, Tamaro Hudson, Radhika Kakarla, Muneer M. Abbas, Nicole M. Anders, Donna Dowling, Serina King, Ashley B. Bruns, William D. Wagner, Charles G. Drake, Emmanuel S. Antonarakis, Mario A. Eisenberger, Samuel R. Denmeade, Michelle A. Rudek, Gary L. Rosner, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2): 306–315.
https://doi.org/10.1158/1078-0432.CCR-17-1100
Published: 15 January 2018
View article titled, Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Open the PDF for Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial in another window
Includes: Supplementary data
Journal Articles

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

Mark N. Stein, Joseph R. Bertino, Howard L. Kaufman, Tina Mayer, Rebecca Moss, Ann Silk, Nancy Chan, Jyoti Malhotra, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Bruce G. Haffty, Robert S. DiPaola, Tracie Saunders, Andrew Zloza, Sherri Damare, Yasmeen Beckett, Bangning Yu, Saltanat Najmi, Christian Gabel, Siobhan Dickerson, Ling Zheng, Wafik S. El-Deiry, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Janice M. Mehnert
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4163–4169.
https://doi.org/10.1158/1078-0432.CCR-16-2658
Published: 01 August 2017
View article titled, First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Open the PDF for First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer

Nitu Bansal, Monica Bartucci, Shamila Yusuff, Stephani Davis, Kathleen Flaherty, Eric Huselid, Michele Patrizii, Daniel Jones, Liangxian Cao, Nadiya Sydorenko, Young-Choon Moon, Hua Zhong, Daniel Medina, John Kerrigan, Mark N. Stein, Isaac Y. Kim, Thomas W. Davis, Robert S. DiPaola, Joseph Bertino, Hatem E. Sabaawy
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6176–6191.
https://doi.org/10.1158/1078-0432.CCR-15-3107
Published: 15 December 2016
View article titled, BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Open the PDF for BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Braña, Desamparados Roda, Brian B. Haines, Theresa Zhang, Christopher G. Winter, Sharda Jha, Youyuan Xu, Jason Frazier, Richard A. Klinghoffer, Ann Leighton-Swayze, Yang Song, Scot Ebbinghaus, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 49–59.
https://doi.org/10.1158/1078-0432.CCR-14-0940
Published: 05 January 2015
View article titled, Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Open the PDF for Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Abiraterone in Prostate Cancer: A New Angle to an Old Problem

Mark N. Stein, Susan Goodin, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 1848–1854.
https://doi.org/10.1158/1078-0432.CCR-11-1805
Published: 01 April 2012
View article titled, Abiraterone in Prostate Cancer: A New Angle to an Old Problem
Open the PDF for Abiraterone in Prostate Cancer: A New Angle to an Old Problem in another window
Journal Articles

Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors

Yaqoob Ali, Yong Lin, Mecide M. Gharibo, Murugesan K. Gounder, Mark N. Stein, Theodore F. Lagattuta, Merrill J. Egorin, Eric H. Rubin, Elizabeth A. Poplin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5876–5882.
https://doi.org/10.1158/1078-0432.CCR-07-0883
Published: 01 October 2007
View article titled, Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors in another window
Journal Articles

CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma

Mark N. Stein, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3765–3770.
https://doi.org/10.1158/1078-0432.CCR-06-2844
Published: 02 July 2007
View article titled, CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma
Open the PDF for CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma in another window